MENU
+Compare
FULC
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$3.85
Change
-$0.00 (-0.00%)
Capitalization
207.66M

FULC Fulcrum Therapeutics Forecast, Technical & Fundamental Analysis

a clinical-stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies.

Industry Biotechnology
FULC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for FULC with price predictions
Feb 21, 2025

FULC's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for FULC turned positive on February 19, 2025. Looking at past instances where FULC's MACD turned positive, the stock continued to rise in of 32 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where FULC's RSI Oscillator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on February 21, 2025. You may want to consider a long position or call options on FULC as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FULC advanced for three days, in of 277 cases, the price rose further within the following month. The odds of a continued upward trend are .

FULC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

FULC moved below its 50-day moving average on January 31, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for FULC crossed bearishly below the 50-day moving average on January 30, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FULC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for FULC entered a downward trend on February 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.807) is normal, around the industry mean (12.481). P/E Ratio (0.000) is within average values for comparable stocks, (84.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.603). FULC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (3.010) is also within normal values, averaging (251.221).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. FULC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FULC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
FULC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

FULC is expected to report earnings to fall 18.91% to -28 cents per share on February 25

Fulcrum Therapeutics FULC Stock Earnings Reports
Q4'24
Est.
$-0.28
Q3'24
Beat
by $0.05
Q2'24
Beat
by $1.28
Q1'24
Beat
by $0.01
Q4'23
Beat
by $0.03
The last earnings report on November 13 showed earnings per share of -34 cents, beating the estimate of -40 cents. With 283.51K shares outstanding, the current market capitalization sits at 207.66M.
A.I. Advisor
published General Information

General Information

a clinical-stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
26 Landsdowne Street
Phone
+1 617 651-8851
Employees
76
Web
https://www.fulcrumtx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RCEAX10.230.15
+1.49%
RBC China Equity A
SSILX11.95-0.09
-0.75%
State Street International Stock Sel A
WFINX54.65-0.96
-1.73%
Allspring Index C
ASVIX10.38-0.24
-2.26%
American Century Small Cap Value Inv
NSRSX48.13-1.76
-3.53%
Neuberger Berman Small Cap Growth R6

FULC and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, FULC has been loosely correlated with SLS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if FULC jumps, then SLS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FULC
1D Price
Change %
FULC100%
N/A
SLS - FULC
48%
Loosely correlated
-3.05%
ANNX - FULC
40%
Loosely correlated
-0.71%
VRDN - FULC
39%
Loosely correlated
-2.11%
MLTX - FULC
34%
Loosely correlated
+0.55%
ITOS - FULC
34%
Loosely correlated
-0.94%
More